Endocrine Society RPHR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Right arrow Help viewing high resolution images
Right arrow Return to article
(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)



FIG. 1. Model of positive and negative signaling to the interferon regulatory factor-1 (IRF-1) gene. (A) A number of mediators positively regulate prolactin (PRL) stimulation of IRF-1 gene transcription. These include PRL-inducible Stat1, the constitutive factor Sp1, and the coactivator p300/CBP, which enhances Stat1 activation of the IRF-1 promoter. (B) PRL-inducible Stat5 inhibits IRF-1 transcription. Although competition for the coactivator p300/CBP appears to be involved (Luo and Yu-Lee, 1997,2000), the in vivo mechanism of inhibition at the IRF-1 promoter is as yet unclear. (C) The IRF-1 promoter can be activated via PRL-inducible Stat1 as well as by tumor necrosis factor alpha (TNF{alpha})-inducible nuclear factor kappa B (NF{kappa}B) binding to their respective response elements. In this model of positive and negative cytokine signal cross talk, Stat1 synergizes with NF{kappa}B but Stat5 antagonizes NF{kappa}B signaling to the IRF-1 promoter. Additional factors that can be recruited by Stats or NF{kappa}B to regulate IRF-1 promoter activity are indicated in gray.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals